Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

Heart

Volumn 85, Issue 3, 2001, Pages 265-271

  Sanmuganathan, P S ^a   Ghahramani, P ^a   Jackson, P R ^a   Wallis, E J ^a   Ramsay, L E ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Aspirin; Coronary heart disease; Meta analysis; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ARTICLE; BLEEDING; CLINICAL TRIAL; CORONARY RISK; DRUG SAFETY; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 0034763373     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.85.3.265     Document Type: Article

References (25)

1. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
2. Aspirin and risk of haemorrhagic stroke. A meta analysis of randomized controlled trials
3. Individualizing aspirin therapy for prevention of cardiovascular events
4. Final report on the aspirin component of the ongoing Physicians' Health Study
5. Thrombosis prevention trial: Randomised trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
6. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
7. Aspirin as a therapeutic agent in cardiovascular disease. A statement for healthcare professionals from the American Heart Association
8. Prophylactic aspirin and the risk of peptic ulcer bleeding
9. Risk of aspirin associated major upper gastrointestinal bleeding with enteric coated or buffered product
10. Randomised trial of prophylactic daily aspirin in British male doctors
11. Risk of major gastrointestinal bleeding with aspirin
12. Large trials with simple protocols: Indications and contraindications
13. Confidence intervals for number needed to treat
14. Coronary and cardiovascular risk estimation for primary prevention: Population validation of a new Sheffield table
15. Determination of who may derive most benefit from aspirin in primary prevention: Subgroup results from a randomised controlled trial
16. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT Study
17. Primary prevention
18. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study
19. Cardiovascular risk profiles
20. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?
21. Prediction of coronary risk for primary prevention of coronary heart disease: A comparison of methods
22. Joint British recommendations on prevention of coronary heart disease in clinical practice
23. British Hypertension Society guidelines for hypertension management 1999: Summary